logo

For the Inventor, By the Inventor

Grayslake, IL, United States of America

James F Kerwin

This inventor holds 14 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Abbott Laboratories Corporation, Other. Active years: 1990-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James F Kerwin. Retrieved from https://idiyas.com/inventor/james-f-kerwin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14

% Patents Active = 100.0

Average Co-Inventor Count = 4.3

ph-index = 8

Forward Citations = 169(Granted Patents)


Location History:

  • Mundelein, IL (US) (1990 - 1994)
  • Grayslake, IL (US) (1994 - 2003)

Company Filing History:

goldMedal12 out of 4,190 
 
Abbott Laboratories Corporation
 patents
silverMedal2 out of 834,601 
Other
 patents

Years Active: 1990-2003

Loading Chart...
Areas of Expertise:
Potassium Channel Openers
Adrenergic Compounds
Nitric Oxide Synthase
Imidazoles
Benzopyranopyrrole
Adenosine Kinase
Amino Acid Analog
Guanidino Compounds
Hexahydrobenz Isoindole
D-Glutamic Acid Derivatives
CCK Antagonists
Bicyclic Compounds
14 patents (USPTO):Explore Patents
1. 6518279 - Cyclopentanone dihydropyridine compounds useful as potassium channel openers (2003-02-11),
2. 6503935 - Imidazoles and related compounds as &agr;1A agonists (2003-01-07),
3. 6046207 - Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adrenergic compounds (2000-04-04),
4. 5891882 - Benzopyranopyrrole and benzopyranopyridine .alpha.-1 adenergic compounds (1999-04-06),
5. 5861294 - Adenosine kinase polypeptides (1999-01-19),
6. 5792767 - Bicyclic substituted hexahydrobenz �e! isoindole alpha-1 adrenergic (1998-08-11),
7. 5597823 - Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic (1997-01-28),
8. 5521181 - Bicyclic substituted hexahydrobenz[e]isoindole .alpha.-1 adrenergic (1996-05-28),
9. 5478946 - Guanidino compounds as regulators of nitric oxide synthase (1995-12-26),
10. 5380945 - Guanidino compounds as regulators of nitric oxide synthase (1995-01-10),
11. 5362747 - 2-nitroaryl and 2-cyanoaryl compounds as regulators of nitric oxide (1994-11-08),
12. 5346907 - Amino acid analog CCK antagonists (1994-09-13),
13. 5128346 - Derivatives of D-glutamic acid and D-aspartic acid (1992-07-07),
14. 4971978 - Derivatives of D-glutamic acid and D-aspartic acid (1990-11-20),

Title: The Innovative Contributions of James F. Kerwin

Introduction

James F. Kerwin is a notable inventor based in Grayslake, Illinois. He has made significant contributions to the field of pharmaceuticals, holding a total of 14 patents. His work primarily focuses on compounds that have therapeutic applications, particularly in the area of potassium channel opening.

Latest Patents

Among his latest patents are "Cyclopentanone dihydropyridine compounds useful as potassium channel openers" and "Imidazoles and related compounds as α1A agonists." These innovations reflect his commitment to advancing medical science and improving patient outcomes through novel chemical compounds.

Career Highlights

Throughout his career, James has worked with prominent organizations, including Abbott Laboratories Corporation. His experience in such a reputable company has allowed him to develop and refine his inventions, contributing to the advancement of pharmaceutical research.

Collaborations

James has collaborated with esteemed colleagues, including William A. Carroll and Michael D. Meyer. These partnerships have fostered a creative environment that has led to groundbreaking innovations in their respective fields.

Conclusion

James F. Kerwin's contributions to the field of pharmaceuticals through his numerous patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of new therapeutic agents that can improve health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…